Clinical Oncology
Volume 21, Issue 7 , Pages 536-542 , September 2009

Radiochemotherapy for Lung Cancer in Developing Countries

  • L. Kepka

      Affiliations

    • Department of Radiation Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    • Corresponding Author InformationAuthor for correspondence: L. Kepka, Department of Radiation Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, ul. Roentgena 5, 02-781 Warsaw, Poland.Tel: +48-22-506118-893; Fax: +48-22-641-87-28.
    • ,
  • F. Casas

      Affiliations

    • Radiation Oncology Department, University Clinic, Barcelona, Spain
    • ,
  • B. Perin

      Affiliations

    • Institute for Lung Diseases, Sremska Kamenica, Serbia
    • ,
  • S. Abdel-Wahab

      Affiliations

    • Department of Radiation Oncology, Ain Shams University, Cairo, Egypt
    • ,
  • T. Saghatelyan

      Affiliations

    • Department of Radiation Oncology, National Cancer Institute, Yerevan, Armenia
    • ,
  • L. Vashkevitch

      Affiliations

    • Department of Radiation Oncology, N. Alexandrov Research Institute of Oncology, Minsk, Belarus
    • ,
  • P.M. Gaye

      Affiliations

    • Institut Dantec, Dakar, Senegal
    • ,
  • D. Dawotola

      Affiliations

    • Department of Radiation Oncology, Zaria, Nigeria
    • ,
  • J.P. Agarwal

      Affiliations

    • Tata Memorial Centre, Mumbai, India
    • ,
  • B. Jeremic

      Affiliations

    • International Atomic Energy Agency, Vienna, Austria

Received 13 March 2009 ,Accepted 1 April 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer. ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:29S–55S
  3. Kepka L, Danilova V, Saghatelyan T, et al. Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: results of an International Atomic Energy Agency (IAEA) survey. Lung Cancer. 2007;56:235–245
  4. Macbeth FR, Abratt RP, Cho KH, Stephens RJ, Jeremic B. Lung cancer management in limited resource settings: guidelines for appropriate good care. Radiother Oncol. 2007;82:123–131
  5. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II. ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:234S–242S
  6. Jeremic B, Classen J, Bamberg M. Radiation therapy alone in technically operable, medically inoperable early stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54:119–130
  7. Jeremic B, Milicic B, Acimovic L, Milisavljevic S. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early stage (I/II) non-small cell lung cancer (NSCLC). Long-term results of a phase II study. J Clin Oncol. 2005;23:6873–6880
  8. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation therapy for stage I non-small cell lung carcinoma: clinical outcomes in 245 patients in a Japanese multi-institutional study. Cancer. 2004;101:1623–1631
  9. Timmerman RD, Kavanagh BD, Chinsoo Cho L, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25:947–952
  10. Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1–2N0) non-small cell lung cancer. Radiother Oncol. 1996;41:41–44
  11. Lester JF, Macbeth FR, Brewster AE, et al. CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer. 2004;45:237–242
  12. Aupérin A, Le Péchoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006;17:473–483
  13. Rolland E, Le Pechoux C, Curran WJ, et al. Concomitant radio-chemotherapy (CT-RT) versus sequential CT-RT in locally advanced non-small-cell lung cancer (NSCLC): a meta analysis using individual patient data (IPD) from randomized clinical trials (RCTs). Int J Radiat Oncol Biol Phys. 2007;69:5S
  14. Jassem J. The role of radiotherapy in lung cancer: where is the evidence?. Radiother Oncol. 2007;83:203–213
  15. Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA*: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;133:243S–265S
  16. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2004;4:CD002140.pub2. DOI:10.1002/14651858.CD002140.pub.2
  17. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006;66:1399–1407
  18. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996;14:1065–1070
  19. Belderbos JSA, Kepka L, Kong Spring F-M, Martel MK, Videtic GMM, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2008;72:335–342
  20. De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol. 2009;20:98–102
  21. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbin in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer. 2004;46:87–98
  22. Cakir S, Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer. 2004;43:309–316
  23. Demiral AN, Alicikus ZA, Ugur VI, et al. Patterns of care for lung cancer in radiation oncology departments of Turkey. Int J Radiat Oncol Biol Phys. 2008;72:1530–1537
  24. Baumann M, Herrmann T, Koch R, et al. Continuous hyperfractionated accelerated radiotherapy – weekend less (CHARTWEL) versus conventionally fractionated (CF) in non-small-cell lung cancer (NSCLC): first results of a phase III randomised multicentre trial (ARO 97–1). Eur J Cancer. 2005;3:S323
  25. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;6:890–895
  26. Pignon JP, Ariagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med. 1992;327:1618–1624
  27. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer. J Clin Oncol. 1997;15:893–900
  28. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group study 9104. J Clin Oncol. 2002;20:3054–3060
  29. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med. 1987;316:912–918
  30. Murray N, Coy P, Pater J, et al. Importance of timing for thoracic P, irradiation in the combined modality treatment of limited stage small cell lung cancer. J Clin Oncol. 1993;11:336–344
  31. Work E, Nielsen O, Bentzen S, et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small cell lung cancer. J Clin Oncol. 1997;15:3030–3037
  32. Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001;12:1231–1238
  33. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22:4785–4793
  34. Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist. 2004;9:665–672
  35. Pijls-Johannesma MCG, de Ruysscher D, Lambin P, et al. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev. 2005;1:CD004700
  36. Jeremic B. Timing of concurrent radiotherapy (RT) and chemotherapy (CHT) in limited disease small cell lung cancer (LD SCLC). Meta-analysis of meta- analyses. Int J Radiat Oncol Biol Phys. 2006;64:981–982
  37. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:2650–2671
  38. Videtic GM, Truong PT, Dar AR, Yu EW, Stitt LW. Shifting from hypofractionated to “conventionally” fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation. Int J Radiat Oncol Biol Phys. 2003;57:709–716
  39. Jeremic B, Shibamoto Y, Nikolic N, et al. The role of radiation therapy in the combined modality treatment of patients with extensive disease small-cell lung cancer (ED SCLC): a randomized study. J Clin Oncol. 1999;17:2092–2099
  40. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–484
  41. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–672
  42. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003;21:3201–3206
  43. Kusumoto S, Koga K, Tsukino H, Nagamachi S, Nishikawa K, Watanabe K. Comparison of survival of patients with lung cancer between elderly (greater than or equal to 70) and younger (70 greater than) age groups. Jpn J Clin Oncol. 1986;16:319–323
  44. Schaake-Koning C, van der Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992;326:524–530
  45. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol. 1995;13:452–458
  46. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys. 2001;50:19–25
  47. Pignon T, Gregor A, Schaake Koning C, Roussel A, Van Glabbeke M, Scalliet P. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol. 1998;46:239–248
  48. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys. 1999;45:1143–1149
  49. Jeremic B, Shibamoto Y, Milicic B, et al. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/oral etoposide in elderly patients with stage III non-small-cell lung cancer. A phase II study. Int J Radiat Oncol Biol Phys. 1999;44:343–348
  50. Quon H, Shepherd FA, Payne DG, et al. The influence of age on the delivery tolerance and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 1999;43:39–45
  51. Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in Intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 2000;89:1953–1960
  52. Schild SE, Stella BJ, Brooks BJ, et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer. 2005;103:2349–2354
  53. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung cancer. A phase II study. Cancer. 1998;82:836–841
  54. Murray N, Grafton C, Shah A, et al. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol. 1998;16:3323–3328
  55. NCCN Clinical Practice Guidelines in Oncology . Small cell lung cancer. Available from: www.nccn.org

PII: S0936-6555(09)00111-3

doi: 10.1016/j.clon.2009.04.001

Clinical Oncology
Volume 21, Issue 7 , Pages 536-542 , September 2009

Article Tools